Zydus consumer revenue rises 73% as segment profit hits Rs 7.1 crore

Zydus Lifesciences Limited reported consumer-products revenue of Rs 1,125.7 crore for the quarter ended September 30, 2026, up 73% year on year, while the segment result was Rs 7.1 crore. Consumer products delivered the fastest revenue growth among Zydus’ three disclosed segments, but its profit was below the Rs 161.3 crore recorded in the preceding quarter.

How fast did Zydus consumer-products revenue grow?

Zydus’ consumer-products revenue rose 73% to Rs 1,125.7 crore in the quarter ended September 30, 2026, from Rs 648.9 crore in the quarter ended September 30, 2025. The increase was Rs 476.8 crore, based on the consolidated unaudited segment figures, and was the highest percentage growth among the three operating segments disclosed.

Consumer products grew faster than pharmaceuticals, where revenue increased 23% to Rs 6,558.2 crore from Rs 5,321.1 crore, and medical technologies, where revenue rose 47% to Rs 225.7 crore from Rs 153.2 crore. Consumer products accounted for about 14% of Zydus’ Rs 7,909.6 crore revenue from operations in the September 2026 quarter.

What was Zydus’ consumer-products segment profit?

Zydus reported a Rs 7.1 crore consumer-products segment result for the quarter ended September 30, 2026, compared with a Rs 17.2 crore segment loss a year earlier. The segment therefore returned to a positive result as revenue increased by Rs 476.8 crore, although the reported profit equalled about 0.6% of quarterly consumer-products revenue.

The September-quarter result was below the Rs 161.3 crore segment result reported for the quarter ended June 30, 2026, when consumer-products revenue was Rs 1,435.9 crore. Revenue declined Rs 310.2 crore quarter on quarter and the segment result declined Rs 154.2 crore. The filing reports the figures but does not give a segment-specific reason for the sequential movement.

How did consumer products compare with Zydus’ other segments?

Zydus’ pharmaceuticals segment remained the largest contributor in the September 2026 quarter, reporting Rs 6,558.2 crore of revenue and a Rs 1,318.6 crore segment result. Consumer products ranked second with Rs 1,125.7 crore of revenue, while medical technologies reported Rs 225.7 crore, placing consumer products well above medical technologies but below pharmaceuticals by revenue.

The segment-profit trend differed from the revenue pattern. Pharmaceuticals increased quarterly revenue by Rs 1,237.1 crore year on year, but its segment result declined from Rs 1,774.9 crore. Consumer products moved from a Rs 17.2 crore loss to a Rs 7.1 crore profit, whereas medical technologies increased revenue by Rs 72.5 crore but its segment loss widened to Rs 92.8 crore from Rs 34.5 crore.

What did Zydus’ half-year consumer-products figures show?

Zydus reported consumer-products revenue of Rs 2,561.6 crore for the half year ended September 30, 2026, compared with Rs 1,506.4 crore for the half year ended September 30, 2025. The increase of Rs 1,055.2 crore was about 70%, while the segment result rose to Rs 168.4 crore from Rs 126.2 crore.

The half-year segment result included Rs 161.3 crore in the June 2026 quarter and Rs 7.1 crore in the September 2026 quarter. Pharmaceuticals generated Rs 12,856.3 crore of half-year revenue and a Rs 2,563.8 crore segment result, compared with consumer products’ Rs 2,561.6 crore revenue and Rs 168.4 crore result. Medical technologies reported Rs 508.7 crore of half-year revenue and a Rs 149.8 crore segment loss.

What assets and liabilities were assigned to Zydus’ consumer-products segment?

Zydus reported consumer-products segment assets of Rs 10,350.8 crore at September 30, 2026, compared with Rs 9,878.3 crore at September 30, 2025 and Rs 10,457.5 crore at June 30, 2026. Consumer-products segment liabilities stood at Rs 4,438.6 crore at September 30, 2026, against Rs 4,173.5 crore a year earlier and Rs 4,520.0 crore three months earlier.

Medical technologies had Rs 6,413.6 crore of segment assets and Rs 6,455.3 crore of liabilities at September 30, 2026, alongside its Rs 92.8 crore quarterly loss. Pharmaceuticals held Rs 38,842.5 crore of assets and Rs 14,390.2 crore of liabilities. Zydus’ total assets were Rs 55,606.9 crore and total liabilities were Rs 25,284.1 crore at the reporting date.

Conclusion

Consumer products delivered Zydus’ fastest year-on-year segment revenue growth in the September 2026 quarter, with sales rising 73% to Rs 1,125.7 crore. Its Rs 7.1 crore segment profit improved on the Rs 17.2 crore loss a year earlier, but it was substantially below the Rs 161.3 crore result in the June 2026 quarter and the Rs 1,318.6 crore generated by pharmaceuticals in September.

What to watch next is whether Zydus can sustain the half-year revenue increase of about 70% while retaining a positive consumer-products segment result after the September-quarter decline. The filing gives no consumer-products profitability target or timetable, while medical technologies remains an unresolved drag, reporting a Rs 92.8 crore quarterly loss despite 47% revenue growth.